Melanotan I 10 mg
Educational recon guide for a 10 mg Melanotan I (afamelanotide-related) research vial. Research use only — not Scenesse implants.
Vial
10 mg
Your BAC water
2 mL
Concentration
5.00 mg/mL
Per unit
~50.0 mcg
Frequency
Daily or near-daily SC in secondary research-vial write-ups (approved product is a long-acting implant)
Route
Subcutaneous (research vials). Approved afamelanotide uses a controlled implant.
Live reconstitution calculator
Defaults match this guide (10 mg + 2 mL BAC). Change water or dose and the unit tables below update automatically.
Step 1
Reconstitution
Peptide amount in the vial and how much bacteriostatic water you add.
Step 2
Your dose
This guide uses microgram-scale research doses — quick picks are in mcg (100 mcg = 0.1 mg).
Quick select (mcg) — switch units or type any value
Suggested: 30-unit barrel (smallest that fits this draw).
Your draw
Results
Total draw
10 units
Volume
0.100 mL
Doses per vial
20
Syringes needed
1
Barrel
30-unit
Fits one syringe?
Yes
30-unit · 0.3 mL
Filled to 10 u
Fill one 30-unit U-100 syringe to about 10 units (0.100 mL).
Research cycle phases
Units and volumes recompute from your Step 1 concentration (2 mL BAC → 5.00 mg/mL · 50.0 mcg/unit). Doses below are once daily during the course — not weekly.
Standard course
Approved afamelanotide (Scenesse) is a 16 mg bioresorbable implant for erythropoietic protoporphyria on a multi-week schedule — not daily research-vial injections. Secondary SC research-vial tables for “Melanotan I” often discuss roughly ~0.5–1 mg class amounts (sometimes lower mcg starts). Treat as recon math only; not a DIY version of Scenesse.
| Phase | Daily dose | Units | Volume |
|---|---|---|---|
| Days 1–7 (intro) | 500 mcg0.5 mg | 10 u | 0.10 mL0.5 mg daily educational start for research vials |
| Days 8–28 (standard educational) | 1 mg1,000 mcg | 20 u | 0.20 mL1 mg daily — common secondary research-vial amount |
Alternate / higher courses
Shorter or higher daily courses discussed in research communities — not a clinical recommendation
| Phase | Daily dose | Units | Volume |
|---|---|---|---|
| Higher educational · 2 mg × 14 days | 2 mg2,000 mcg | 40 u | 0.40 mLHigher research-vial discussion amount — not implant therapy |
Supplies planner
Using the guide’s phase ladder (500 mcg → 1 mg per injection (phase ladder)) over a 28-day course. Set a dose in Step 2 to plan supplies at your own amount.
Your recon
2 mL · 5.00 mg/mL
Dose in plan
Phase ladder
Syringe size
100-unit
Horizon
28-day course
Melanotan I 10 mg vials
3 vials
~24.5 mg mg total peptide over this 28-day course at 500 mcg → 1 mg per injection (phase ladder). Each vial holds 10 mg.
Bacteriostatic water
2 × 3 mL or 1 × 10 mL
2 mL BAC per vial × 3 vials = 6.0 mL total. Buy as 2× 3 mL bottles or 1× 10 mL bottle (whichever you stock).
U-100 insulin syringes (100-unit)
28+ syringes
About one 100-unit syringe per injection for this schedule. Keep a few spares.
Alcohol swabs & sharps
~62 swabs · 1 sharps container
Wipe vial stopper and injection site each time. Dispose needles in a proper sharps container.
Reconstitution steps
- Allow the lyophilized 10 mg Melanotan I vial and bacteriostatic water to reach room temperature.
- Draw 2.0 mL bacteriostatic water (default for this guide).
- Inject BAC slowly down the inner wall of the vial — avoid blasting the powder cake.
- Gently swirl or roll until the solution is clear. Do not shake hard (foaming).
- Label with recon date and concentration (e.g. "5.0 mg/mL — 2 mL BAC").
- Refrigerate at 2–8 °C (35–46 °F), protected from light. Prefer using a reconstituted multi-dose vial within ~28 days with sterile technique.
Storage
Lyophilized
Keep dry powder cold and dark when possible (−20 °C / −4 °F preferred for long-term research stock).
Reconstituted
Refrigerate at 2–8 °C (35–46 °F). Avoid freeze–thaw of the working solution. Prefer finishing within ~28 days.
- ·Write recon date and BAC volume on the label.
- ·Protect from light during storage.
- ·Discard if cloudy, particulates, or odd odor appear after reconstitution.
Protocol notes
- ·More MC1R-selective narrative than MT-II, but research vials ≠ approved Scenesse implants.
- ·Research use only.
Research context & considerations
Afamelanotide is an approved implant for specific photodermatosis care in some regions. Research-market “Melanotan I” vials are a different, unregulated supply channel.
- ·Nausea and pigmentation changes can occur.
- ·Mole/freckle darkening — dermatology caution.
- ·Not a substitute for approved EPP therapy.
- ·Pregnancy out of scope.
Catalog match
MelanotanI
10mg x 10 vials · from $20